An official website of the United States government
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Trial Status: complete
Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety,
pharmacodynamics, pharmacokinetics, and hematologic response in subjects with
International Prognostic Scoring System (IPSS) risk category of low-risk or
Intermediate-1 MDS. This study will be conducted in two phases. In phase 1 subjects will
be randomized into 3 cohorts in a 28-day cycles. Phase 2, 80 new subjects will be
randomized in a 1:1 ratio into 2 doses/schedules.
Inclusion Criteria
Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent before the first study-specific procedure.
Men or women ≥18 years with IPSS low risk or Int-1 MDS (all subjects). Subjects must have had at least 1 of the following disease-related criteria during the 8 weeks before randomization:
Red blood cell (RBC) transfusion dependence of 2 or more units of RBC transfusions (RBC transfusion administered for hemoglobin (Hb) levels ≤9.0 g/dL are counted).
Hb of <9.0 g/dL in at least 2 blood counts prior to randomization or in 1 blood count if RBC transfusion was received.
Absolute Neutrophil Count (ANC) of <0.5 × 10^9/L in at least 2 blood counts prior to randomization.
Platelet counts of <50 × 10^9/L in at least 2 blood counts prior to randomization.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Adequate organ function.
Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.
Women of child-bearing potential must agree to use contraceptive measures of birth control for 6 months after completing treatment; men must use contraceptive measures and agree not to father a child for at least 3 months after completing treatment.
Exclusion Criteria
Treatment with any investigational drug or therapy within 2 weeks before study treatment.
Treatments for MDS must be concluded 1 month prior to study treatment.
Prior treatment with azacitidine, decitabine, or guadecitabine.
Diagnosis of chronic myelomonocytic leukemia (CMML).
Poor medical risk because of other conditions such as uncontrolled systemic diseases or active uncontrolled infections.
Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer or breast cancer under control with hormone therapy, or other cancer from which the subject has been disease free for at least 1 year.
Known active infection with human immunodeficiency virus or hepatitis viruses.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03502668.
Locations matching your search criteria
United States
Kansas
Fairway
University of Kansas Clinical Research Center
Status: Active
Name Not Available
Westwood
University of Kansas Hospital-Westwood Cancer Center
Status: Active
Name Not Available
Texas
Houston
M D Anderson Cancer Center
Status: Active
Name Not Available
A Phase 1-2, multicenter, open-label study of various ASTX727 LD doses and schedules to
assess the safety, pharmacodynamics (PD), pharmacokinetics (PK), and hematologic response
in subjects with IPSS risk category of low-risk or Intermediate-1 MDS. The study will be
conducted in 2 phases.
Phase 1: In Stage A, subjects will be randomized into 3 cohorts of 6 subjects each
testing different doses of oral decitabine with cedazuridine in 28-day cycles. When
safety has been established in Phase 1 Stage A, Phase 1 Stage B will open, wherein
additional 30 subjects will be randomized in a 1:1:1 ratio into 3 cohorts of 10 subjects.
Phase 2: Using 2 doses/schedules one of which will be selected from Phase 1, 40
additional subjects per dose/schedule will be randomized in a 1:1 ratio. The selected
doses/schedules will be evaluated for safety (drug-related AEs), efficacy (including
